158
Participants
Start Date
July 16, 2021
Primary Completion Date
March 15, 2026
Study Completion Date
August 15, 2026
AVA6000
AVA6000 is a FAP-activated doxorubicin.
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
NOT_YET_RECRUITING
University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow
RECRUITING
St James's University Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds
RECRUITING
The Royal Marsden, NHS Foundation Trust, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
RECRUITING
The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle upon Tyne
NOT_YET_RECRUITING
Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Lead Sponsor
Avacta Life Sciences Ltd
INDUSTRY